159 related articles for article (PubMed ID: 37509257)
1. Chemoradiotherapy Combined with Brachytherapy for the Definitive Treatment of Esophageal Carcinoma.
Mangesius J; Hörmandinger K; Jäger R; Skvortsov S; Plankensteiner M; Maffei M; Seppi T; Dejaco D; Santer M; Sarcletti M; Ganswindt U
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509257
[TBL] [Abstract][Full Text] [Related]
2. Impact of radical dose escalation by endoluminal brachytherapy and induction chemotherapy in the definitive treatment of locally advanced esophageal cancer - A retrospective study.
Raghunath S; Tiwari R; Rashmi S; Geetha SN; Sulthana R; Madabhavi I
J Cancer Res Ther; 2022 Dec; 18(Supplement):S280-S284. PubMed ID: 36510977
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study.
Halder A; Biswas R; Ghosh A; Dastidar AG
J Contemp Brachytherapy; 2018 Jun; 10(3):225-231. PubMed ID: 30038642
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
Yorozu A; Dokiya T; Oki Y
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):271-5. PubMed ID: 10487545
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
9. Definitive Radiotherapy for Primary Squamous Cell Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate Brachytherapy Boost the Best Treatment? Experience of Two Italian Institutes.
Laliscia C; Gadducci A; Fabrini MG; Barcellini A; Guerrieri ME; Parietti E; Ursino S; Morganti R; Cafaro I; Paiar F
Oncol Res Treat; 2017; 40(11):697-701. PubMed ID: 29065399
[TBL] [Abstract][Full Text] [Related]
10. Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix.
Forrest JL; Ackerman I; Barbera L; Barnes EA; Davidson M; Kiss A; Thomas G
Int J Gynecol Cancer; 2010 Aug; 20(6):1074-8. PubMed ID: 20683420
[TBL] [Abstract][Full Text] [Related]
11. A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus.
Tudu R
South Asian J Cancer; 2020; 9(1):20-22. PubMed ID: 31956613
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
Gaspar LE; Qian C; Kocha WI; Coia LR; Herskovic A; Graham M
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):593-9. PubMed ID: 9112458
[TBL] [Abstract][Full Text] [Related]
13. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
Mayer A; Nemeskéri C; Petneházi C; Borgulya G; Varga S; Naszály A
Strahlenther Onkol; 2004 Apr; 180(4):209-15. PubMed ID: 15057431
[TBL] [Abstract][Full Text] [Related]
14. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
15. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
[TBL] [Abstract][Full Text] [Related]
16. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?
Sun Myint A; Mukhopadhyay T; Ramani VS; Perkins K; Snee AJ; Jelley F; Wong H; Lee CD
Colorectal Dis; 2010 Aug; 12 Suppl 2():30-6. PubMed ID: 20618365
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
[TBL] [Abstract][Full Text] [Related]
18. Definitive high-dose-rate endobronchial brachytherapy of bronchial stump for lung cancer after surgery.
Skowronek J; Piorunek T; Kanikowski M; Chicheł A; Bielęda G
Brachytherapy; 2013; 12(6):560-6. PubMed ID: 23850277
[TBL] [Abstract][Full Text] [Related]
19. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
20. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
